Consolidated Statements of Operations - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue
Operating expenses:
General and administrative		12,388	7,665
Research and development		10,963	6,630
Total operating expenses		23,351	14,295
Loss from operations		(23,351)	(14,295)
Other income (expense):
Interest expense		(53,000)	(33)
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note		(5,327)	(559)
Offering costs - Senior Secured Convertible Note and Senior Convertible Note		(660)	(550)
Debt extinguishments loss - Senior Secured Convertible Notes		(6,497)	(1,831)
Other income (expense), net		(12,537)	(2,973)
Loss before provision for income tax		(35,888)	(17,268)
Provision for income taxes
Net loss before noncontrolling interests		(35,888)	(17,268)
Net loss attributable to the noncontrolling interests		1,612	811
Net loss attributable to PAVmed Inc.		(34,276)	(16,457)
Less: Series B Convertible Preferred Stock dividends earned		(287)	(270)
Net loss attributable to PAVmed Inc. common stockholders		$ (34,563)	$ (16,727)
Per share information:
Net loss per share attributable to PAVmed Inc. - basic and diluted		$ (0.72)	$ (0.54)
Net loss per share attributable to PAVmed Inc. common stockholders - basic and diluted		$ (0.73)	$ (0.55)
Weighted average common shares outstanding, basic and diluted	[1]	47,432,115	30,197,458

[1] Basic weighted-average number of shares of common stock outstanding for the years ended December 31, 2020 and 2019 include the shares of the Company issued and outstanding during the years ended December 31, 2020 and December 31, 2019, each on a weighted average basis. The basic weighted average number of shares outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive.